И. В. Жиров

4 ta ish

National Medical Research Center of Cardiology

1. Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

   С. Н. Терещенко, М. В. Шестакова, Ф. Т. Агеев +7

   Maqola20202 iqtibos

   ABIABI:AkademIndex/2026.other.282517

2. Cardiovascular prevention 2022. Russian national guidelines

   S. А. Boytsov, Nana Pogosova, А. А. Аншелес +34

   Maqola20232 iqtibos

   ABIABI:AkademIndex/2026.other.282555

3. Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022)

   И Е Чазова, Yu. V. Zhernakova, N. V. Blinova +19

   MaqolaOAOchiq kirishCardiac Health and Mental HealthEurasian heart journal20220 iqtibos

   ABIABI:AkademIndex/2022.article.000532

4. Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022)

   И Е Чазова, Yu. V. Zhernakova, N. V. Blinova +20

   MaqolaCardiac Health and Mental HealthEurasian heart journal20220 iqtibos

   ABIABI:AkademIndex/2022.article.009850